<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: N4 Pharma agree 14 month research deal with Nanomerics Ltd	</title>
	<atom:link href="https://ukinvestormagazine.co.uk/n4-pharma-agree-14-month-research-deal-with-nanomerics-ltd/feed/" rel="self" type="application/rss+xml" />
	<link>https://ukinvestormagazine.co.uk/n4-pharma-agree-14-month-research-deal-with-nanomerics-ltd/</link>
	<description>UK Investor Magazine provides breaking financial news and investment ideas</description>
	<lastBuildDate>Tue, 25 Feb 2020 12:42:45 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0.2</generator>
	<item>
		<title>
		By: N4 Pharma narrow loss across 2019 - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/n4-pharma-agree-14-month-research-deal-with-nanomerics-ltd/#comment-14472</link>

		<dc:creator><![CDATA[N4 Pharma narrow loss across 2019 - UK Investor Magazine]]></dc:creator>
		<pubDate>Tue, 25 Feb 2020 12:42:45 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=26963#comment-14472</guid>

					<description><![CDATA[[&#8230;] firm added that it is working to improve Nuvec dispersion to address in-vivo [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] firm added that it is working to improve Nuvec dispersion to address in-vivo [&#8230;]</p>
]]></content:encoded>
		
			</item>
	</channel>
</rss>
